The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Jun. 09, 2015

Filed:

Mar. 08, 2012
Applicants:

Michael H. Cardone, Dorchester, MA (US);

Andrew F. Kolodziej, Winchester, MA (US);

David Richard, Littleton, MA (US);

Inventors:

Michael H. Cardone, Dorchester, MA (US);

Andrew F. Kolodziej, Winchester, MA (US);

David Richard, Littleton, MA (US);

Assignee:

Eutropics Pharmaceuticals, Inc., Cambridge, MA (US);

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A61K 31/04 (2006.01); C07D 215/38 (2006.01); C07D 401/14 (2006.01); C07D 405/14 (2006.01); C07D 417/14 (2006.01);
U.S. Cl.
CPC ...
C07D 401/14 (2013.01); C07D 405/14 (2013.01); C07D 417/14 (2013.01);
Abstract

The present invention relates to a compositions for and methods of cancer treatment in which compounds of Formula I or Formula II. In some aspects, the treatment of B-cell Lymphoma or other hematopoietic cancers is encompassed. In other aspects, the invention provides methods for treating particular types of hematopoietic cancers, such as B-cell lymphoma, using a combination of one or more compounds of Formula I or Formula II. Combination therapy with, for example, a class of therapeutics known as 26S proteasome inhibitors, for example, Bortezomib, are also included. In another aspect the present invention relates to autoimmune treatment with compounds of Formula I or Formula II. In another aspect, this invention relates to methods for identifying compounds, for example, compounds of the BH3 mimic class, that have unique in vitro properties that predict in vivo efficacy against B-cell lymphoma tumors and other cancers as well as autoimmune disease.


Find Patent Forward Citations

Loading…